AUSTIN, Texas, Feb. 8, 2013 /PRNewswire/ -- Vermillion, Inc. (NASDAQ: VRML), a molecular diagnostics company focused on gynecologic cancers and vascular medicine, will hold a conference call on Wednesday, February 20, 2013, at 4:30 p.m. ET to discuss preliminary results for its fourth quarter and full year 2012 ended December, 31, 2012. Select preliminary unaudited results will be issued in a press release prior to the call. Vermillion's interim CEO Bruce A. Huebner will host the call, followed by a question and answer period. Date: Wednesday, February 20, 2013 Time: 4:30 p.m. Eastern time ( 1:30 p.m. Pacific time) Dial-In Number: 1-800-909-4761 International: 1-212-231-2934 Conference ID#: 21648726 Webcast: http://edge.media-server.com/m/p/e247e2q2/lan/en The conference call will be webcast live and available for replay via the investor section of the company's website at www.vermillion.com. Please call the conference telephone number 5-10 minutes prior to the start time. An operator will register your name and organization. If you have any difficulty connecting with the conference call, please contact Liolios Group at 1-949-574-3860. A replay of the call will be available approximately two hours after the call through March 6, 2013. Toll-free replay number: 1-800-633-8284 International replay number: 1-402-977-9140 Replay pin number: 21648726 About Vermillion Vermillion, Inc. (NASDAQ: VRML) is dedicated to the discovery, development and commercialization of novel high-value diagnostic tests that help physicians diagnose, treat and improve outcomes for patients. Vermillion, along with its prestigious scientific collaborators, has diagnostic programs in oncology, vascular medicine and women's health. Additional information about Vermillion can be found at www.vermillion.com. Investor Relations Contact: Liolios Group, Inc. Ron Both Tel 1-949-574-3860 email@example.com SOURCE Vermillion, Inc.